VIGMED GRANTED PATENT FOR ITS FIRST CLOSED SYSTEM IV CATHETERS

The Swedish Patent and Registration Office (PRV) has announced to Vigmed that it intends to approve the Company’s patent application for their closed system, needle protecting I.V. catheters.

The patent is Vigmed's first for a so-called “closed I.V. system”, and an international patent application has been filed. A closed IV system reduces the risk of infection in comparison to a conventional IV catheter.  This new patent will take Vigmed and their safety products to an even higher level of safety and patient security.

"This particular product patent is important as it gives the Company the rights that will be applied to other future product types for closed systems - whether specially designed for the Asian, European or American markets”, says Fredrik Thorne Vigmed R&D Director.

Vigmed's product design is far more cost effective than the security products for closed I.V. systems available in the market today. Products in the closed IV system segment command greater premiums compared to standard IV systems.

Vigmed has filed more than 60 patents and patent applications internationally which are based on 10 patent families. The company owns all its patents and patent applications without any restrictions. The basic patents all have a maximum validity period.

Vigmed’s strategy is to protect the Company's technology and products in all geographical areas deemed to be of importance. Vigmed intends to expand its patent portfolio continuously on both the offensive and defensive patent and utility model rights.

For further information contact:

CEO, Finn Ketler 46 42 600 5311 or R&D Director, Fredrik Thörne 46 42 600 5312

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.

Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor

Tags: